PRRT2 and prostate cancer: Consistently verified and quantified by PSA enhancer-promoter luciferase reporter assays, this PKC-mediated inhibition of AR activity is consistent with the aforementioned mechanisms describing the nuclear exclusion of AR in prostate cancer cells secondary to melatonin treatment.